Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Moderna Inc (NQ: MRNA )

72.89 -0.55 (-0.75%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,425,370
Open 73.44
Bid (Size) 72.50 (1)
Ask (Size) 72.70 (5)
Prev. Close 73.44
Today's Range 71.65 - 73.60
52wk Range 62.55 - 170.47
Shares Outstanding 384,000,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Is It Time to Buy August's Worst-Performing Nasdaq Stocks?
These tech stocks got hit hard last month. Should you buy the dip? 
Via The Motley Fool
Moderna's Investigational Mpox Vaccine More Effective Than Current Approved Shot, Animal Study Shows
Moderna is conducting a Phase 1/2 trial of mRNA-1769, a potential mpox vaccine for adults. Early research shows it may outperform Bavarian Nordic's Jynneos in reducing severe disease in monkeys. 
Via Benzinga

Performance

YTD
-35.21%
-35.21%
1 Month
-13.56%
-13.56%
3 Month
-50.95%
-50.95%
6 Month
-34.91%
-34.91%
1 Year
-32.28%
-32.28%

More News

Read More
Jim Cramer: Oklo Is Losing Money 'Hand-Over-Fist,' But This Private Equity Stock Is A Buy
Via Benzinga
EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's COVID-19 mRNA Vaccine Targeting the SARS-COV-2 Variant JN.1
Via ACCESSWIRE
Moderna, Inc. Shareholders - Robbins LLP Reminds MRNA Stockholders of the Class Action Lawsuit Against the Company – Seek Counsel Today
From Robbins LLP
Via GlobeNewswire
Smart Money Is Betting Big In MRNA Options
Via Benzinga
Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031
Via FinancialNewsMedia
Exposures COVID-19
Is It Time to Buy August's Worst-Performing S&P 500 Stocks?
Via The Motley Fool
Topics Stocks
Exposures US Equities
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Moderna, PDD Holdings, Extreme Networks, and Sprinklr and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Wellness In Your Personal Life Unleashes Productivity At Work
Via Investor's Business Daily
Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031
From FN Media Group LLC
Via GlobeNewswire
UK, Taiwan Approve Moderna's Updated COVID-19 Shot
Via Benzinga
Exposures COVID-19
Moderna Unusual Options Activity
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Moderna Receives Medicines And Healthcare Products Regulatory Agency (MHRA) Authorization For Updated COVID-19 Vaccine Targeting SARS-COV-2 Variant JN.1
Via ACCESSWIRE
MODERNA, INC. (NASDAQ: MRNA) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Moderna, Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
Taiwan Food & Drug Administration Approves Moderna’s COVID-19 mRNA Vaccine Targeting the SARS-COV-2 Variant JN.1
Via ACCESSWIRE
Magnificent 7 Miss Out, 2 Cybersecurity Stocks Stand Firm, Retailers Lag In Volatile August: Here Are The Top S&P 500 Gainers And Losers
Via Benzinga
Topics Stocks
Exposures US Equities
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Moderna, PDD Holdings, Extreme Networks, and Sprinklr and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Moderna And BioNTech Bet On Personalized Cancer Vaccines To Revive Fortunes After Dwindling COVID-19 Vaccine Sales
Via Benzinga
Exposures COVID-19
Shareholder Rights Law Firm Robbins LLP Urges Moderna, Inc. Stockholders to Seek Counsel for the MRNA Class Action
From Robbins LLP
Via GlobeNewswire
This Moderna Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Wednesday
Via Benzinga
Chinese E-Commerce Giant Drops 35% In 2 Days, But Analysts See 92% Upside Potential
Via Benzinga
INVESTOR ALERT:   Shareholder Class Action Lawsuit Filed Against Moderna, Inc. (NASDAQ: MRNA); Investors with Losses Encouraged to Discuss Their Options with Counsel
From DiCello Levitt LLP
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Moderna, PDD Holdings, Extreme Networks, and Sprinklr and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback